Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintains a $26 price target.
February 09, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Phathom Pharmaceuticals with a $26 price target.
The reiteration of a Buy rating and maintenance of a $26 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Phathom Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100